Cardiology

U.S. Concierge Medicine Market to Reach $13.3 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022 - 5:21pm

The "U.S. Concierge Medicine Market Size, Share & Trends Analysis Report by Application (Primary Care, Internal Medicine, Cardiology, Psychiatry), by Ownership (Standalone, Group), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Concierge Medicine Market Size, Share & Trends Analysis Report by Application (Primary Care, Internal Medicine, Cardiology, Psychiatry), by Ownership (Standalone, Group), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. concierge medicine market size is expected to reach USD 13.3 billion by 2030.
  • The market is expected to expand at a CAGR of 10.27% over the forecast period.
  • This, coupled with more time with physicians, fewer hospitalizations, and focus on preventive care are driving the growth of the market.

Onduo by Verily and Sword Health partner to accelerate adoption of comprehensive, precision care approach

Retrieved on: 
Wednesday, August 17, 2022 - 5:14pm

Onduo by Verily, an Alphabet precision health company, announced today a strategic collaboration with Sword Health, the fastest-growing digital musculoskeletal (MSK) care provider, to offer complementary solutions to each companys employer customers and their employees.

Key Points: 
  • Onduo by Verily, an Alphabet precision health company, announced today a strategic collaboration with Sword Health, the fastest-growing digital musculoskeletal (MSK) care provider, to offer complementary solutions to each companys employer customers and their employees.
  • Guided by evidence-based medical care and informed by data, Onduo helps employers and health plans deliver precision health at scale.
  • Onduo provides a whole-person care solution featuring digital, connected care with a human touch for diabetes, hypertension, weight loss and diabetes prevention.
  • Onduo LLC and a network of affiliated professional entities (collectively, Onduo) collaborate to offer certain care management and coordinated clinical care programs.

Digital Biomarkers Drug Development Market Report 2022: Transformational Growth for Clinical Trials via Enhancements to Patient Recruitment, Stratification, Monitoring, and Drug Response Comprehension

Retrieved on: 
Wednesday, August 17, 2022 - 5:30pm

Digital Biomarkers Enable Quality-of-life Assessments in Cancer Patients, Which Have Importance in Oncology Clinical Trials

Key Points: 
  • Digital Biomarkers Enable Quality-of-life Assessments in Cancer Patients, Which Have Importance in Oncology Clinical Trials
    Cardiology Complications Lead to Millions of Deaths Every Year, Costing Significant Economic and Healthcare Losses
    Digital Biomarkers Enable Remote Data Collection, Enhancing Safety Signal Accuracy and Eliminating Patient Inconvenience
    Public Funding Focuses on Evaluating Novel Digital Biomarkers for Early Disease Diagnoses, Such as Cancer and Neurological Diseases
    Digital Biomarker Innovations Focus on Mobile Application, Software, and Analysis Algorithm Development
    Growth Opportunity 2: Digital Vocal Biomarkers for Remote, Contactless, Continuous, and Accurate Patient Monitoring in Clinical Trials

Telehealth Market Worth $539.73 Billion by 2029 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

Retrieved on: 
Wednesday, August 17, 2022 - 3:00pm

Similarly, reluctance to migrate from traditional systems, chances ofmisdiagnosis, and technological barriers in developing countries may pose challenges to market players.

Key Points: 
  • Similarly, reluctance to migrate from traditional systems, chances ofmisdiagnosis, and technological barriers in developing countries may pose challenges to market players.
  • Based on application, the telehealth market is segmented into psychiatry, radiology, cardiology, primary care, dermatology, remote ICU, and other applications.
  • Quick Buy Telehealth Market Research Report: https://www.meticulousresearch.com/Checkout/33290201
    Based on end user, the healthcare providers segment is estimated to account for the largest share of the market in 2022.
  • The telehealth market has witnessed several new product launches, approvals, partnerships & agreements, and acquisitions in recent years.

Telehealth Market Worth $539.73 Billion by 2029 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

Retrieved on: 
Wednesday, August 17, 2022 - 3:00pm

Similarly, reluctance to migrate from traditional systems, chances ofmisdiagnosis, and technological barriers in developing countries may pose challenges to market players.

Key Points: 
  • Similarly, reluctance to migrate from traditional systems, chances ofmisdiagnosis, and technological barriers in developing countries may pose challenges to market players.
  • Based on application, the telehealth market is segmented into psychiatry, radiology, cardiology, primary care, dermatology, remote ICU, and other applications.
  • Quick Buy Telehealth Market Research Report: https://www.meticulousresearch.com/Checkout/33290201
    Based on end user, the healthcare providers segment is estimated to account for the largest share of the market in 2022.
  • The telehealth market has witnessed several new product launches, approvals, partnerships & agreements, and acquisitions in recent years.

Boston Scientific Announces Upcoming Conference Schedule

Retrieved on: 
Tuesday, August 16, 2022 - 7:00pm

MARLBOROUGH, Mass., Aug. 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor events.

Key Points: 
  • MARLBOROUGH, Mass., Aug. 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor events.
  • On Wednesday, September 7, 2022, Mike Mahoney, chairman and chief executive officer, and Lauren Tengler, vice president, Investor Relations, will participate in a 30-minute fireside chat with the host analyst at the Wells Fargo 2022 Healthcare Conference.
  • On Sunday, September 18, the company will host an investor event and live webcast from 9:00 a.m. 10:00 a.m. EDT at the 34th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation.
  • Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.

Growth Opportunities for Digital Biomarkers in Drug Development - Focus on Neurology, Oncology, and Cardiology - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 16, 2022 - 5:03pm

Digital Biomarkers Enable Quality-of-life Assessments in Cancer Patients, Which Have Importance in Oncology Clinical Trials

Key Points: 
  • Digital Biomarkers Enable Quality-of-life Assessments in Cancer Patients, Which Have Importance in Oncology Clinical Trials
    Cardiology Complications Lead to Millions of Deaths Every Year, Costing Significant Economic and Healthcare Losses
    Digital Biomarkers Enable Remote Data Collection, Enhancing Safety Signal Accuracy and Eliminating Patient Inconvenience
    Public Funding Focuses on Evaluating Novel Digital Biomarkers for Early Disease Diagnoses, Such as Cancer and Neurological Diseases
    Digital Biomarker Innovations Focus on Mobile Application, Software, and Analysis Algorithm Development
    Growth Opportunity 2: Digital Vocal Biomarkers for Remote, Contactless, Continuous, and Accurate Patient Monitoring in Clinical Trials
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220816005776/en/

With 3Brain AG's Accura-3D microchip, a first-in-class cell-electronic interface enters the market

Retrieved on: 
Tuesday, August 16, 2022 - 3:00pm

Accura-3D will allow researchers to explore new biological questions at unprecedented depths and resolution and discover pharmacologically relevant biomarkers.

Key Points: 
  • Accura-3D will allow researchers to explore new biological questions at unprecedented depths and resolution and discover pharmacologically relevant biomarkers.
  • 3Brain AG's bidirectional pixel array technology at the heart of Accura-3D is expanding non-destructive functional imaging beyond optic and optogenetic approaches.
  • Accura-3D chips are fully compatible with existing hardware devices to give users exciting results from day 1.
  • After being the first to develop and introduce CMOS-based HD-MEA (high-density microelectrode array), 3Brain has now created another first-in-class technology with Accura-3D.

AliveCor Announces Series F Financing to Help Expand Offerings to Key Healthcare Industry Stakeholders

Retrieved on: 
Tuesday, August 16, 2022 - 2:00pm

MOUNTAIN VIEW, Calif., Aug. 16, 2022 /PRNewswire/ -- AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced its Series F Financing led by GE Healthcare.

Key Points: 
  • MOUNTAIN VIEW, Calif., Aug. 16, 2022 /PRNewswire/ -- AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced its Series F Financing led by GE Healthcare.
  • These subscription services are supported by the company's personal ECG devices, including KardiaMobile, KardiaMobile 6L, and KardiaMobile Card.
  • This financing will also allow for continued advancements in AliveCor's AI roadmap and pipeline of innovations.
  • "This financing will help accelerate our growth into new strategic sectors and markets, enabling us to connect even more people to life-saving remote heart care."

HeartBeam Announces FDA Submission of HeartBeam AIMI™ Product

Retrieved on: 
Tuesday, August 16, 2022 - 1:42pm

I am proud of the HeartBeam team for their commitment to achieving this critical step in bringing the Companys technology to market.

Key Points: 
  • I am proud of the HeartBeam team for their commitment to achieving this critical step in bringing the Companys technology to market.
  • We look forward to working through the FDA review process toward our goal of clearance for the US market.
  • HeartBeam AIMI is software as a medical device with a 510(K) regulatory pathway.
  • We look forward to approval and offering our HeartBeam AIMI platform in an expected $500 million total addressable market.